Replies to post #452436 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

the journal publication has encountered some tough and difficult obstacles and that NWBO had therefore decided to postpone the publication and still go for RA approval.

no I never said NWBO decided to postpone the publication. I said the natural cause of things, obstacles in the publication, is making it all take longer which is for us all to witness and NWBO is witnessing that as well.

My message is. They are far in the MHRA process and in the near future, there will be that announcement of MHRA good news + topline data ex or including the journal but ex if need be. Now how I happen to know that I cant tell you exactly but Im in a circle where people talk with Les.

Also what information do you have that NWBO had requested an MHRA approval and if the MHRA had dismissed the request, production of DCVax-L in the UK would have already been terminated?

I called the MHRA and asked them if in general, not NWBO, a biotech can keep selling treatment for a life-threatening cancer disease for commercial reasons without evidence of efficiency or approval and they said no, they would step in with a certain procedure. For what it is worth. I will get an email about this and share it when I have received it.